Nevertheless, a recent study investigated the possibility of reprogramming GAMMs to improve glioblastoma therapies by targeting the CSF-1R using three CSF-1R inhibitors, PLX3397, BLZ945, and GW2580, on GAMMs isolated from patient tumors. The gene discussed is CSF1R; the disease is glioblastoma.